Study of Niacin on Endothelial Function in HIV-infected Subjects With Low High Density Lipoprotein Cholesterol Levels
This study has been completed.
Sponsor:
University of Hawaii
Collaborator:
Information provided by (Responsible Party):
Dominic Chow, University of Hawaii
ClinicalTrials.gov Identifier:
NCT00986986
First received: September 29, 2009
Last updated: November 19, 2012
Last verified: July 2012
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
This study is a pilot study examining the effect of extended-release niacin (Niaspan ®) on flow-mediated vasodilation (FMD) of the brachial artery, among human immunodeficiency virus (HIV)-1 infected individuals with low high density lipoprotein (HDL). Brachial artery diameter will be measured by high-resolution ultrasound at entry and week 12 of study. The primary comparisons will be change in FMD from baseline to 12 weeks within each of the two arms. The second specific aim will be to investigate the proportion of the effect of extended-release niacin on other known cardiovascular markers.
| Condition | Intervention |
|---|---|
|
HIV Infections Dyslipidemia Endothelial Dysfunction |
Drug: extended release niacin |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Prospective Randomized Pilot Study of the Effect of Niaspan on Endothelial Function in HIV-infected Subjects With Low HDL Cholesterol Levels |
Resource links provided by NLM:
Further study details as provided by University of Hawaii:
Primary Outcome Measures:
- Change in Flow-mediated Vasodilation (FMD) From Baseline to Study Week 12 [ Time Frame: Two time points (baseline and study week 12) ] [ Designated as safety issue: No ]Brachial arterial flow-mediated dilation (FMD), assessed by high-resolution ultrasonography, reflects endothelium-dependent vasodilator function. The primary outcome is the change in FMD from baseline to study week 12.
- Flow Mediated Vasodilation [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]Flow mediated vasodilation is a marker of endothelial function
Secondary Outcome Measures:
- High-density Lipoprotein Cholesterol (HDL) Change From Baseline to Study Week 12 [ Time Frame: Two time points (baseline and study week 12) ] [ Designated as safety issue: No ]HDL, often referred to "Good cholesterol levels", will be obtained in both arms. HDL is a marker of coronary heart disease.
- HDL [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
| Enrollment: | 20 |
| Study Start Date: | November 2007 |
| Study Completion Date: | April 2010 |
| Primary Completion Date: | April 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Active Drug (extended release niacin)
Subjects in this arm will be given 12 weeks of extended release niacin. Intervention: extended release niacin (Niaspan) starting at 500 mg by mouth daily and titrated to a maximum dose of 1500 mg by mouth daily. Titration will depend on patient tolerability.
|
Drug: extended release niacin
Active arm subjects will start extended release niacin (Niaspan) at 500 mg per night (by mouth once a daily) and titrate to a maximum tolerated dose (not exceeding 1500 mg per night (by mouth once a day) for 12 weeks. Titration will depend on patient tolerability of Niaspan.
Other Name: Niaspan
|
|
No Intervention: Observation
Subjects in this arm will be monitored for 12 weeks and will not receive extended release niacin
|
Show Detailed Description Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Age ≥18 years
- Documented HIV infection
- Subjects must have taken HAART 6 months prior to study entry and must be on stable HAART (no dose change to antiretroviral medications) for at least 30 days immediately prior to study entry
- HDL < 40 mg/dL • LDL < 130 mg/dL
- All subjects with reproductive potential should utilize adequate contraception for the duration of this study and for at least 12 weeks following permanent discontinuation of study treatment. Acceptable methods include male condom, female condom, diaphragm, or intra-uterine device (IUD)
Exclusion Criteria:
- Known cardiac disease
- Arrhythmia
- History of angina
- Uncontrolled hypertension
- Pregnancy
- Breast-feeding
- Medication known to influence vasodilatation such as nitrates, metformin, pioglitazone, and rosiglitazone
- Heavy use of vitamin supplements
- Diagnosis of diabetes mellitus
- Treatment with lipid-lowering drugs within 6 weeks prior to study
- Hemoglobin <9.0 mg/dL
- Absolute neutrophil count <750 cells/mm3
- Platelet count <75,000 platelets/ mm3
- Alanine aminotransferase (ALT or SGOT)/ aspartate aminotransferase (AST or SGPT) / alkaline phosphatase > 2.5 x upper limit of normal (ULN)
- Creatinine >1.5 x ULN
- Individuals with an infection or other medical illness requiring hospitalization within 14 days prior to study entry
- Individuals who have active alcohol or drug abuse which, in the investigator's opinion, is sufficient to prevent adequate compliance with study therapy and evaluations
- Prior history of hypersensitivity reaction to niacin or any other component of the study drug
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00986986
Locations
| United States, Hawaii | |
| University of Hawaii - Hawaii Center for AIDS | |
| Honolulu, Hawaii, United States, 96816 | |
Sponsors and Collaborators
University of Hawaii
Investigators
| Principal Investigator: | Dominic C Chow, MD | University of Hawaii - Hawaii Center for AIDS |
More Information
Publications:
| Responsible Party: | Dominic Chow, Associate Professor of Medicine and Pediatrics, University of Hawaii |
| ClinicalTrials.gov Identifier: | NCT00986986 History of Changes |
| Other Study ID Numbers: | ENDO, Department of Defense |
| Study First Received: | September 29, 2009 |
| Results First Received: | August 14, 2011 |
| Last Updated: | November 19, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by University of Hawaii:
|
Human immunodeficiency virus Low high density lipoprotein Endothelial function Flow-mediated vasodilation |
Additional relevant MeSH terms:
|
HIV Infections Acquired Immunodeficiency Syndrome Dyslipidemias Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases Lipid Metabolism Disorders Metabolic Diseases Niacin |
Nicotinic Acids Niacinamide Vasodilator Agents Cardiovascular Agents Therapeutic Uses Pharmacologic Actions Hypolipidemic Agents Antimetabolites Molecular Mechanisms of Pharmacological Action Lipid Regulating Agents Vitamin B Complex Vitamins Micronutrients Growth Substances Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on May 23, 2013